News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

January 26, 2021 Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
January 21, 2021 Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021
January 7, 2021 Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
January 5, 2021 Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 10, 2020 Apellis and Sobi Report Positive Top-line Results at 48 Weeks from the Phase 3 PEGASUS Study of Pegcetacoplan in PNH
December 7, 2020 Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH
November 30, 2020 Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx Conference
November 19, 2020 Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan
November 16, 2020 Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
November 13, 2020 Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual